Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy: a cross-sectional analysis

Shaelyn Ward; Kade Ezell; Audrey Wise; Morgan Garrett; Brayden Rucker; Drew Lestersmith; Mohammed Emam; Matt Vassar

doi:10.2217/rme-2023-0058

Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy: a cross-sectional analysis

Shaelyn Ward, Kade Ezell, Audrey Wise, Morgan Garrett, Brayden Rucker, Drew Lestersmith, Mohammed Emam, Matt Vassar

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Our objectives are: to evaluate the completeness of harms reporting in systematic reviews (SRs) on platelet-rich plasma therapy; to assess the overall methodological quality of the SR using AMSTAR-2 tool; to assess harms reporting overlap in primary studies between SRs. Materials & methods: The authors searched five database systems for relevant literature on platelet rich plasma therapy. The authors screened and extracted in masked, duplicate fashion. Results: All SRs reported less than 50% completeness in harms reporting. The most frequently reported item was harms being stated in the abstract or title (26/103, 25.2%). AMSTAR-2 assessed 96 SRs as 'critically low', 6 SRs as 'low' and 1 'moderate'. Conclusion: Our study highlights that reporting of harms should become more standardized and transparent.

Original language	English
Pages (from-to)	531-542
Number of pages	12
Journal	Regenerative Medicine
Volume	18
Issue number	7
DOIs	https://doi.org/10.2217/rme-2023-0058
State	Published - 1 Jul 2023

Keywords

PRP
cell therapy
harms
plasma
platelet-rich plasma
regeneration
repair
therapy

Access to Document

10.2217/rme-2023-0058

Cite this

@article{6b4dc7cc3c474cb3b45317005b30234f,

title = "Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy: a cross-sectional analysis",

abstract = "Aim: Our objectives are: to evaluate the completeness of harms reporting in systematic reviews (SRs) on platelet-rich plasma therapy; to assess the overall methodological quality of the SR using AMSTAR-2 tool; to assess harms reporting overlap in primary studies between SRs. Materials \& methods: The authors searched five database systems for relevant literature on platelet rich plasma therapy. The authors screened and extracted in masked, duplicate fashion. Results: All SRs reported less than 50\% completeness in harms reporting. The most frequently reported item was harms being stated in the abstract or title (26/103, 25.2\%). AMSTAR-2 assessed 96 SRs as 'critically low', 6 SRs as 'low' and 1 'moderate'. Conclusion: Our study highlights that reporting of harms should become more standardized and transparent.",

keywords = "PRP, cell therapy, harms, plasma, platelet-rich plasma, regeneration, repair, therapy",

author = "Shaelyn Ward and Kade Ezell and Audrey Wise and Morgan Garrett and Brayden Rucker and Drew Lestersmith and Mohammed Emam and Matt Vassar",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = jul,

day = "1",

doi = "10.2217/rme-2023-0058",

language = "English",

volume = "18",

pages = "531--542",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy

T2 - a cross-sectional analysis

AU - Ward, Shaelyn

AU - Ezell, Kade

AU - Wise, Audrey

AU - Garrett, Morgan

AU - Rucker, Brayden

AU - Lestersmith, Drew

AU - Emam, Mohammed

AU - Vassar, Matt

PY - 2023/7/1

Y1 - 2023/7/1

N2 - Aim: Our objectives are: to evaluate the completeness of harms reporting in systematic reviews (SRs) on platelet-rich plasma therapy; to assess the overall methodological quality of the SR using AMSTAR-2 tool; to assess harms reporting overlap in primary studies between SRs. Materials & methods: The authors searched five database systems for relevant literature on platelet rich plasma therapy. The authors screened and extracted in masked, duplicate fashion. Results: All SRs reported less than 50% completeness in harms reporting. The most frequently reported item was harms being stated in the abstract or title (26/103, 25.2%). AMSTAR-2 assessed 96 SRs as 'critically low', 6 SRs as 'low' and 1 'moderate'. Conclusion: Our study highlights that reporting of harms should become more standardized and transparent.

AB - Aim: Our objectives are: to evaluate the completeness of harms reporting in systematic reviews (SRs) on platelet-rich plasma therapy; to assess the overall methodological quality of the SR using AMSTAR-2 tool; to assess harms reporting overlap in primary studies between SRs. Materials & methods: The authors searched five database systems for relevant literature on platelet rich plasma therapy. The authors screened and extracted in masked, duplicate fashion. Results: All SRs reported less than 50% completeness in harms reporting. The most frequently reported item was harms being stated in the abstract or title (26/103, 25.2%). AMSTAR-2 assessed 96 SRs as 'critically low', 6 SRs as 'low' and 1 'moderate'. Conclusion: Our study highlights that reporting of harms should become more standardized and transparent.

KW - PRP

KW - cell therapy

KW - harms

KW - plasma

KW - platelet-rich plasma

KW - regeneration

KW - repair

KW - therapy

UR - https://www.scopus.com/pages/publications/85164063947

U2 - 10.2217/rme-2023-0058

DO - 10.2217/rme-2023-0058

M3 - Article

C2 - 37340904

AN - SCOPUS:85164063947

SN - 1746-0751

VL - 18

SP - 531

EP - 542

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 7

ER -

Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy: a cross-sectional analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this